$PODD
INSULET CORP

2013 Q2 Form 10-Q Financial Statement

#000114519713000009 Filed on May 08, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2013 Q1 2012 Q1
Revenue $60.09M $57.36M $47.75M
YoY Change 17.75% 20.11% 68.99%
Cost Of Revenue $33.26M $32.20M $27.46M
YoY Change 15.87% 17.27% 86.47%
Gross Profit $26.83M $25.16M $20.30M
YoY Change 20.16% 23.94% 49.97%
Gross Profit Margin 44.65% 43.86% 42.5%
Selling, General & Admin $27.48M $26.97M $25.76M
YoY Change 4.38% 4.68% 58.84%
% of Gross Profit 102.41% 107.2% 126.92%
Research & Development $5.174M $4.396M $5.432M
YoY Change -20.66% -19.07% 18.37%
% of Gross Profit 19.28% 17.48% 26.76%
Depreciation & Amortization $2.860M $2.904M $2.844M
YoY Change 7.52% 2.11% 144.54%
% of Gross Profit 10.66% 11.54% 14.01%
Operating Expenses $32.66M $31.36M $31.19M
YoY Change -0.59% 0.55% 49.91%
Operating Profit -$5.822M -$6.206M -$10.90M
YoY Change -44.65% -43.04% 49.8%
Interest Expense $0.00 $0.00 -$3.800M
YoY Change -100.0% -100.0% 46.15%
% of Operating Profit
Other Income/Expense, Net -$4.579M -$4.328M -$3.839M
YoY Change 17.77% 12.74% 49.09%
Pretax Income -$10.40M -$10.53M -$14.73M
YoY Change -27.81% -28.51% 49.61%
Income Tax $118.0K $131.0K $46.00K
% Of Pretax Income
Net Earnings -$10.52M -$10.67M -$14.78M
YoY Change -27.33% -27.84% 50.08%
Net Earnings / Revenue -17.5% -18.59% -30.95%
Basic Earnings Per Share
Diluted Earnings Per Share -$195.2K -$201.5K -$310.9K
COMMON SHARES
Basic Shares Outstanding 53.43M shares 53.10M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q2 2013 Q1 2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $150.9M $148.1M $83.00M
YoY Change 115.26% 78.43% -20.57%
Cash & Equivalents $150.9M $148.1M $83.01M
Short-Term Investments
Other Short-Term Assets $6.600M $6.400M $4.300M
YoY Change 53.49% 48.84% 138.89%
Inventory $5.979M $9.199M $14.70M
Prepaid Expenses
Receivables $33.65M $31.11M $26.20M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $197.1M $194.8M $128.2M
YoY Change 69.26% 51.89% -3.96%
LONG-TERM ASSETS
Property, Plant & Equipment $29.33M $24.98M $19.95M
YoY Change 36.93% 25.24% 39.49%
Goodwill $37.54M $37.54M $37.54M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.886M $2.056M $2.647M
YoY Change -24.65% -22.33% 140.64%
Total Long-Term Assets $89.02M $86.14M $87.46M
YoY Change 2.07% -1.51% 467.94%
TOTAL ASSETS
Total Short-Term Assets $197.1M $194.8M $128.2M
Total Long-Term Assets $89.02M $86.14M $87.46M
Total Assets $286.2M $280.9M $215.7M
YoY Change 40.49% 30.24% 44.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.44M $8.544M $16.11M
YoY Change -16.41% -46.95% 159.79%
Accrued Expenses $20.28M $18.02M $12.92M
YoY Change 49.8% 39.53% 48.46%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $14.73M
YoY Change -100.0%
Total Short-Term Liabilities $33.85M $42.98M $32.58M
YoY Change -21.53% 31.92% 93.93%
LONG-TERM LIABILITIES
Long-Term Debt $108.7M $106.2M $110.8M
YoY Change 9.35% -4.2% 56.34%
Other Long-Term Liabilities $2.246M $2.186M $2.040M
YoY Change 8.61% 7.16% 36.0%
Total Long-Term Liabilities $110.9M $108.4M $112.9M
YoY Change 9.33% -4.0% 55.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $33.85M $42.98M $32.58M
Total Long-Term Liabilities $110.9M $108.4M $112.9M
Total Liabilities $147.8M $151.4M $145.5M
YoY Change 2.23% 4.05% 63.26%
SHAREHOLDERS EQUITY
Retained Earnings -$502.7M -$492.2M -$444.5M
YoY Change 9.54% 10.74%
Common Stock $54.00K $53.00K $48.00K
YoY Change 12.5% 10.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $138.3M $129.5M $70.22M
YoY Change
Total Liabilities & Shareholders Equity $286.2M $280.9M $215.7M
YoY Change 40.49% 30.24% 44.85%

Cashflow Statement

Concept 2013 Q2 2013 Q1 2012 Q1
OPERATING ACTIVITIES
Net Income -$10.52M -$10.67M -$14.78M
YoY Change -27.33% -27.84% 50.08%
Depreciation, Depletion And Amortization $2.860M $2.904M $2.844M
YoY Change 7.52% 2.11% 144.54%
Cash From Operating Activities $4.370M -$1.200M -$8.903M
YoY Change -139.3% -86.52% 13.18%
INVESTING ACTIVITIES
Capital Expenditures -$1.630M $1.069M $1.699M
YoY Change -36.08% -37.08% -41.35%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.630M -$1.069M -$1.699M
YoY Change -36.08% -37.08% -41.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $94.36M $633.0K
YoY Change 14806.95% -74.83%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 130.0K $93.04M -$347.0K
YoY Change -83.95% -26912.97% -117.55%
NET CHANGE
Cash From Operating Activities 4.370M -$1.200M -$8.903M
Cash From Investing Activities -1.630M -$1.069M -$1.699M
Cash From Financing Activities 130.0K $93.04M -$347.0K
Net Change In Cash 2.870M $90.77M -$10.95M
YoY Change -122.32% -929.04% 24.62%
FREE CASH FLOW
Cash From Operating Activities $4.370M -$1.200M -$8.903M
Capital Expenditures -$1.630M $1.069M $1.699M
Free Cash Flow $6.000M -$2.269M -$10.60M
YoY Change -170.01% -78.6% -1.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9361000 USD
CY2013Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
8544000 USD
CY2012Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
39921000 USD
CY2013Q1 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
37832000 USD
CY2013Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
31110000 USD
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
33294000 USD
CY2013Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18022000 USD
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19026000 USD
CY2011Q4 us-gaap Acquired Finite Lived Intangible Asset Amount
AcquiredFiniteLivedIntangibleAssetAmount
32900000 USD
CY2013Q1 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P10Y
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
525679000 USD
CY2013Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
621710000 USD
CY2012Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2600000 USD
CY2013Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3000000 USD
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6627000 USD
CY2013Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6722000 USD
CY2013Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2908000 USD
CY2012Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2452000 USD
CY2012Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1700000 USD
CY2013Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1400000 USD
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9841775 shares
CY2012Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9528703 shares
CY2012Q4 us-gaap Assets
Assets
198059000 USD
CY2013Q1 us-gaap Assets
Assets
280899000 USD
CY2013Q1 us-gaap Assets Current
AssetsCurrent
194757000 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
109936000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57293000 USD
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
148065000 USD
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
83006000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93955000 USD
CY2012Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-10949000 USD
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
90772000 USD
CY2013Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53301450 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48359063 shares
CY2013Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53301450 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48359063 shares
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
48000 USD
CY2013Q1 us-gaap Common Stock Value
CommonStockValue
53000 USD
CY2012 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.19
CY2013Q1 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.11
CY2013Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
32201000 USD
CY2012Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
27458000 USD
CY2013Q1 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
103000 USD
CY2012Q1 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
20000 USD
CY2013Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
37831000 USD
CY2012Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
40591000 USD
CY2012Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
2004000 USD
CY2013Q1 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
1855000 USD
CY2012Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
26000 USD
CY2013Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
28000 USD
CY2013Q1 us-gaap Deferred Revenue
DeferredRevenue
1700000 USD
CY2012Q4 us-gaap Deferred Revenue
DeferredRevenue
5400000 USD
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5445000 USD
CY2013Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1661000 USD
CY2013Q1 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
500000 USD
CY2012Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
500000 USD
CY2013Q1 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
700000 USD
CY2012Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
700000 USD
CY2012Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2844000 USD
CY2013Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2904000 USD
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2013Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
30200000 USD
CY2013Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
11332000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
32900000 USD
CY2013Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
32900000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
22963000 USD
CY2013Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
21568000 USD
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13094000 USD
CY2012Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13020000 USD
CY2012Q4 us-gaap Goodwill
Goodwill
37536000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
9937000 USD
CY2013Q1 us-gaap Goodwill
Goodwill
37536000 USD
CY2013Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2013Q1 us-gaap Gross Profit
GrossProfit
25155000 USD
CY2012Q1 us-gaap Gross Profit
GrossProfit
20296000 USD
CY2013Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-10534000 USD
CY2012Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-14734000 USD
CY2013Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
131000 USD
CY2012Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
46000 USD
CY2013Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-857000 USD
CY2012Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3906000 USD
CY2012Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
49000 USD
CY2013Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3784000 USD
CY2012Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2865000 USD
CY2013Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-5668000 USD
CY2012Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-12000 USD
CY2013Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
319000 USD
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1903000 USD
CY2012Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
729000 USD
CY2013Q1 us-gaap Interest And Debt Expense
InterestAndDebtExpense
4355000 USD
CY2012Q1 us-gaap Interest And Debt Expense
InterestAndDebtExpense
3867000 USD
CY2012Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
11785000 USD
CY2013Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7298000 USD
CY2012Q4 us-gaap Inventory Net
InventoryNet
14867000 USD
CY2013Q1 us-gaap Inventory Net
InventoryNet
9199000 USD
CY2013Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
463000 USD
CY2012Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1487000 USD
CY2012Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1595000 USD
CY2013Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
1438000 USD
CY2012Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
28000 USD
CY2013Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
27000 USD
CY2012Q4 us-gaap Liabilities
Liabilities
153883000 USD
CY2013Q1 us-gaap Liabilities
Liabilities
151352000 USD
CY2013Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
280899000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
198059000 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
48286000 USD
CY2013Q1 us-gaap Liabilities Current
LiabilitiesCurrent
42980000 USD
CY2013Q1 us-gaap Long Term Debt
LongTermDebt
120919000 USD
CY2012Q4 us-gaap Long Term Debt
LongTermDebt
118159000 USD
CY2013Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
14733000 USD
CY2012Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
14429000 USD
CY2013Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
106186000 USD
CY2012Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
103730000 USD
CY2013Q1 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of the Business</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is primarily engaged in the development, manufacturing and sale of its proprietary OmniPod Insulin Management System (the &#8220;OmniPod System&#8221;), an innovative, discreet and easy-to-use insulin infusion system for people with insulin-dependent diabetes. The OmniPod System is the only commercially-available insulin infusion system of its kind. The OmniPod System features a unique disposable tubeless OmniPod which is worn on the body for approximately three days at a time and the handheld, wireless Personal Diabetes Manager (&#8220;PDM&#8221;). Conventional insulin pumps re</font><font style="font-family:inherit;font-size:10pt;">quire people with insulin-dependent diabetes to learn to use, manage and wear a number of cumbersome components, including up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">42</font><font style="font-family:inherit;font-size:10pt;"> inches of tubing. In contrast, the OmniPod System features only two discreet, easy-to-use devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates</font><font style="font-family:inherit;font-size:10pt;"> wirelessly and integrates a blood glucose meter. The Company believes that the OmniPod System&#8217;s unique proprietary design offers significant lifestyle benefits to people with insulin-dependent diabetes.</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To support the sales of the OmniPod System, in June 2011, the Company acquired Neighborhood Holdings, Inc. and its wholly-owned subsidiaries (collectively, &#8220;Neighborhood Diabetes&#8221;) in order to expand the Company&#8217;s full suite diabetes management product offerings and obtain access to a larger number of insulin dependent patients. Through Neighborhood Diabetes, the Company is able to provide customers with blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals and has the ability to process claims as either durable medical equipment or through pharmacy benefits.</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved the original OmniPod System in January 2005, and the Company began commercial sale in the United States in October 2005. The Company received CE Mark approval for the original OmniPod System in April 2009.</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has also expanded the availability of the OmniPod System internationally through its partnership with Ypsomed Distribution AG (&#8220;Ypsomed&#8221;) and GlaxoSmithKline (&#8220;GSK&#8221;). In January 2010, the Company entered into a distribution agreement with Ypsomed pursuant to which Ypsomed became the exclusive distributor of the OmniPod System in multiple countries. In February 2011, the Company entered into a distribution agreement with GSK pursuant to which GSK became the exclusive distributor of the OmniPod System in Canada. The Company has focused its efforts on the development and regulatory approval as well as on the manufacturing process of its new OmniPod System. In August 2011, the Company received CE Mark approval, and in December 2012 the Company received 510(k) clearance by the FDA for its new OmniPod System. The new OmniPod System is more than one-third smaller and one-quarter lighter than the original model, while maintaining the same features and operating capabilities. Ypsomed began selling the new OmniPod System in certain countries in Europe in 2012. The Company began selling the new OmniPod System to new customers in the U.S. during the first quarter of 2013.</font></div></div>
CY2012Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-347000 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
93041000 USD
CY2012Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1699000 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1069000 USD
CY2012Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8903000 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1200000 USD
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-10665000 USD
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-14780000 USD
CY2011Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1960000 USD
CY2013Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2012Q1 us-gaap Operating Expenses
OperatingExpenses
31191000 USD
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
31361000 USD
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10895000 USD
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6206000 USD
CY2013Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2215000 USD
CY2013Q1 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1046000 USD
CY2013Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
45000 USD
CY2013Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
1124000 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2202000 USD
CY2013Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2056000 USD
CY2012Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
25000 USD
CY2013Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
20000 USD
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1867000 USD
CY2013Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2186000 USD
CY2012Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3839000 USD
CY2013Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4328000 USD
CY2012Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
980000 USD
CY2013Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1320000 USD
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1069000 USD
CY2012Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1699000 USD
CY2013Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6383000 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4482000 USD
CY2012Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
633000 USD
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
94361000 USD
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
97800000 USD
CY2012Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2033000 USD
CY2013Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2249000 USD
CY2012Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1992000 USD
CY2007Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
535000 shares
CY2012Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12739000 USD
CY2013Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
13871000 USD
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2995000 USD
CY2012Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2609000 USD
CY2012Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
863000 USD
CY2013Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
821000 USD
CY2013Q1 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
1428000 USD
CY2012Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
1129000 USD
CY2013Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
619000 USD
CY2012Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
801000 USD
CY2013Q1 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
876000 USD
CY2012Q1 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
874000 USD
CY2013Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24982000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25422000 USD
CY2013Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1327000 USD
CY2012Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
899000 USD
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5432000 USD
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4396000 USD
CY2013Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-492216000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-481551000 USD
CY2013Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
20.75
CY2013Q1 us-gaap Sales Revenue Net
SalesRevenueNet
57356000 USD
CY2012Q1 us-gaap Sales Revenue Net
SalesRevenueNet
47754000 USD
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.51
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.24
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
26648000 USD
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2165687 shares
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.62
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
20.21
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
23.30
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1519136 shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.22
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1587000 USD
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
31181 shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
173900 shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
29261000 USD
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2517112 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2502190 shares
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
22242000 USD
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y5M18D
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M18D
CY2013Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4715000 shares
CY2013Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
127797 shares
CY2013Q1 us-gaap Stockholders Equity
StockholdersEquity
129547000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
44176000 USD
CY2013Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
100000 USD
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
100000 USD
CY2013Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates in Preparation of Financial Statements</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. The most significant estimates used in these financial statements include the valuation of stock-based compensation expense, accounts receivable, inventories, goodwill, deferred revenue and equity instruments, the lives of property and equipment and intangible assets, as well as warranty and doubtful accounts allowance reserve calculations. Actual results may differ from those estimates.</font></div></div>
CY2012Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47607449 shares
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53052400 shares
CY2013 podd Expected Decrease In Uncertain Tax Positions
ExpectedDecreaseInUncertainTaxPositions
100000 USD
CY2012Q1 podd Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
4536000 USD
CY2013Q1 podd Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
-1826000 USD
CY2012Q1 podd Maximum Annualauthorized Share Increaes
MaximumAnnualauthorizedShareIncreaes
725000 shares
CY2013Q1 podd Number Of Customers With Greater Than Ten Percent Accounts Receivable Balance
NumberOfCustomersWithGreaterThanTenPercentAccountsReceivableBalance
0 customer
CY2012Q4 podd Number Of Customers With Greater Than Ten Percent Accounts Receivable Balance
NumberOfCustomersWithGreaterThanTenPercentAccountsReceivableBalance
2 customer
CY2013Q1 podd Number Of Financial Institution
NumberOfFinancialInstitution
2 location
CY2013Q1 podd Number Of Inches Of Tubing In Conventional Insulin Pump
NumberOfInchesOfTubingInConventionalInsulinPump
42 in
CY2013Q1 podd Number Of Single Source Suppliers
NumberOfSingleSourceSuppliers
1 customer
CY2012Q4 podd Number Of Single Source Suppliers
NumberOfSingleSourceSuppliers
1 customer
CY2013Q1 podd Percentage Of Total Accounts Receivables
PercentageOfTotalAccountsReceivables
0.10
CY2013Q1 podd Proceeds Of Issuance Of Common Stock Net Of Expenses
ProceedsOfIssuanceOfCommonStockNetOfExpenses
92800000 USD
CY2013Q1 podd Product Warranty Term
ProductWarrantyTerm
P4Y
CY2013Q1 podd Renewal Option Terms Additional Period
RenewalOptionTermsAdditionalPeriod
P5Y
CY2013Q1 podd Return Period
ReturnPeriod
P45D
CY2013Q1 podd Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitures
0.16
CY2013Q1 dei Amendment Flag
AmendmentFlag
false
CY2013Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2013Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013Q1 dei Document Period End Date
DocumentPeriodEndDate
2013-03-31
CY2013Q1 dei Document Type
DocumentType
10-Q
CY2013Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001145197
CY2013Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
53434429 shares
CY2013Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2013Q1 dei Entity Registrant Name
EntityRegistrantName
INSULET CORP
CY2013Q1 dei Trading Symbol
TradingSymbol
PODD

Files In Submission

Name View Source Status
0001145197-13-000009-index-headers.html Edgar Link pending
0001145197-13-000009-index.html Edgar Link pending
0001145197-13-000009.txt Edgar Link pending
0001145197-13-000009-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
podd-20130331.xml Edgar Link completed
podd-20130331.xsd Edgar Link pending
podd-20130331_cal.xml Edgar Link unprocessable
podd-20130331_def.xml Edgar Link unprocessable
podd-20130331_lab.xml Edgar Link unprocessable
podd-20130331_pre.xml Edgar Link unprocessable
podd-2013x0331x10xq.htm Edgar Link pending
podd-ex311_2013331xq1.htm Edgar Link pending
podd-ex312_2013331xq1.htm Edgar Link pending
podd-ex321_2013331xq1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending